Genmab ( (GMAB) ) has issued an announcement.
On April 22, 2025, Genmab A/S announced the continuation of its share buy-back program, which was initiated on March 25, 2025. The program aims to repurchase up to 2.2 million shares to reduce capital and fulfill commitments under the Restricted Stock Unit program, with completion expected by July 10, 2025. From April 14 to April 18, 2025, Genmab repurchased 271,629 shares at a total value of 348,658,796.05 DKK, bringing the accumulated total to 1,355,531 shares. This strategic move is expected to impact the company’s capital structure and reflect its confidence in long-term growth.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score of 83 reflects its strong financial health and promising earnings outlook. The company’s impressive revenue and profit growth, coupled with strategic investments, position it well for future success. The technical analysis indicates some caution due to potential downward pressure, while the valuation suggests a balanced risk-reward scenario. Minor concerns about reliance on key products are noted but do not overshadow the company’s strong fundamentals.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, Genmab has a strong presence across North America, Europe, and Asia Pacific. The company is committed to transforming the lives of people with cancer and other serious diseases through its proprietary pipeline, which includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators.
YTD Price Performance: -4.43%
Average Trading Volume: 1,633,579
Technical Sentiment Signal: Buy
Current Market Cap: $12.22B
Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.